Although therapeutic risks such as infections, malignancies, and infusion reactions exist, the more than 20 years of use of anti-TNF in IBD and in other immune-mediated diseases have shown that they are safer drugs even than conventional immunosuppression [98]. The gene discussed is TNF; the disease is inflammatory bowel disease.